Announcement from the annual general meeting in Xbrane Biopharma AB
Idag, 17:30
The annual general meeting 2026 (the "AGM") of Xbrane Biopharma AB ("Xbrane" or the "Company") was held today on 5 May 2026 and the following resolutions were passed by the meeting.
Adoption of the income statement and the balance sheet
The AGM resolved to adopt the income statement and the balance sheet in Xbrane and the consolidated income statement and the consolidated balance sheet.
Allocation of profit
The AGM resolved not to pay any dividend to the shareholders and that the previously accrued profits, including the share premium account and year result would be carried forward.
Discharge from liability
The board of directors and the managing director were discharged from liability for the financial year 2025.
Election of the board of directors and auditor and remuneration
The AGM resolved, in accordance with the nomination committee's proposal, that the board of directors shall comprise four directors. It was also resolved that the number of auditors shall be one registered audit firm.
It was resolved, in accordance with the nomination committee's proposal, that the remuneration is to be SEK 2,215,000 in total, including remuneration for committee work (SEK 2,483,000 previous year), and shall be paid to the board of directors and the members of the established committees in the following amounts:
- SEK 336,000 (SEK 327,000) for each of the directors and SEK 674,000 (SEK 655,000) to the chairman;
- SEK 53,000 (SEK 52,000) for each of the members of the remuneration committee and SEK 107,000 (SEK 104,000) to the chairman of the committee; and
- SEK 80,000 (SEK 78,000) for each of the members of the audit committee and 160,000 (SEK 156,000) to the chairman of the committee.
It was further resolved that the auditor shall be entitled to a fee in accordance with approved invoice.
The AGM resolved, in accordance with the nomination committee's proposal, to re-elect the directors Eva Nilsagård, Mats Thorén, Anders Tullgren and Kirsti Gjellan. Anders Tullgren was re-elected as chairman of the board. Kristoffer Bissessar had declined re-election.
PricewaterhouseCoopers AB was re-elected as the Company's auditor in accordance with the nomination committee's proposal. PricewaterhouseCoopers AB had announced that the authorized auditor Magnus Lagerberg continues as main responsible auditor.
Approval of the remuneration report
The AGM resolved to approve the remuneration report for the financial year 2025.
Adoption of guidelines for remuneration to senior executives
The AGM resolved, in accordance with the board of directors' proposal, to adopt guidelines for remuneration to senior executives to apply until further notice.
Authorization for the board of directors to issue shares, convertibles and/or warrants
The AGM resolved, in accordance with the board of directors' proposal, to authorize the board of directors during the period up until the next annual general meeting, on one or more occasions, to resolve to issue shares, convertibles and/or warrants, with or without preferential rights for the shareholders, corresponding to not more than 25 percent of the share capital of the Company after completed issuances based on the number of shares at the time of the annual general meeting, to be paid in cash, in kind and/or by way of set-off.
For detailed terms regarding the resolutions at the AGM as described above, please refer to the notice and the complete proposals which are available on the Company's website, www.xbrane.com.
Contacts
Martin Åmark, CEO
E: martin.amark@xbrane.com
Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
Attachments
Announcement from the annual general meeting in Xbrane Biopharma AB
Ämnen i artikeln
Announcement from the annual general meeting in Xbrane Biopharma AB
Idag, 17:30
The annual general meeting 2026 (the "AGM") of Xbrane Biopharma AB ("Xbrane" or the "Company") was held today on 5 May 2026 and the following resolutions were passed by the meeting.
Adoption of the income statement and the balance sheet
The AGM resolved to adopt the income statement and the balance sheet in Xbrane and the consolidated income statement and the consolidated balance sheet.
Allocation of profit
The AGM resolved not to pay any dividend to the shareholders and that the previously accrued profits, including the share premium account and year result would be carried forward.
Discharge from liability
The board of directors and the managing director were discharged from liability for the financial year 2025.
Election of the board of directors and auditor and remuneration
The AGM resolved, in accordance with the nomination committee's proposal, that the board of directors shall comprise four directors. It was also resolved that the number of auditors shall be one registered audit firm.
It was resolved, in accordance with the nomination committee's proposal, that the remuneration is to be SEK 2,215,000 in total, including remuneration for committee work (SEK 2,483,000 previous year), and shall be paid to the board of directors and the members of the established committees in the following amounts:
- SEK 336,000 (SEK 327,000) for each of the directors and SEK 674,000 (SEK 655,000) to the chairman;
- SEK 53,000 (SEK 52,000) for each of the members of the remuneration committee and SEK 107,000 (SEK 104,000) to the chairman of the committee; and
- SEK 80,000 (SEK 78,000) for each of the members of the audit committee and 160,000 (SEK 156,000) to the chairman of the committee.
It was further resolved that the auditor shall be entitled to a fee in accordance with approved invoice.
The AGM resolved, in accordance with the nomination committee's proposal, to re-elect the directors Eva Nilsagård, Mats Thorén, Anders Tullgren and Kirsti Gjellan. Anders Tullgren was re-elected as chairman of the board. Kristoffer Bissessar had declined re-election.
PricewaterhouseCoopers AB was re-elected as the Company's auditor in accordance with the nomination committee's proposal. PricewaterhouseCoopers AB had announced that the authorized auditor Magnus Lagerberg continues as main responsible auditor.
Approval of the remuneration report
The AGM resolved to approve the remuneration report for the financial year 2025.
Adoption of guidelines for remuneration to senior executives
The AGM resolved, in accordance with the board of directors' proposal, to adopt guidelines for remuneration to senior executives to apply until further notice.
Authorization for the board of directors to issue shares, convertibles and/or warrants
The AGM resolved, in accordance with the board of directors' proposal, to authorize the board of directors during the period up until the next annual general meeting, on one or more occasions, to resolve to issue shares, convertibles and/or warrants, with or without preferential rights for the shareholders, corresponding to not more than 25 percent of the share capital of the Company after completed issuances based on the number of shares at the time of the annual general meeting, to be paid in cash, in kind and/or by way of set-off.
For detailed terms regarding the resolutions at the AGM as described above, please refer to the notice and the complete proposals which are available on the Company's website, www.xbrane.com.
Contacts
Martin Åmark, CEO
E: martin.amark@xbrane.com
Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
Attachments
Announcement from the annual general meeting in Xbrane Biopharma AB
Ämnen i artikeln
Rapporter
Rapporter
Marknadsöversikt
1 DAG %
Senast
1 mån
